Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol dose escalation versus creatinine clearance-based dosing in gout
ACTRN12611000845932Phase 4Completed
- Sponsor
- Lisa Stamp
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of allopurinol in gout (2 arms), sponsored by Lisa Stamp. Primary endpoints: Reduction in serum urate from baseline and Occurrence of allopurinol-related adverse effects. Started Feb 2012; status: completed.
02
Drugs
allopurinol
03
Conditions
gout
Beyond the preview
Go deeper on ACTRN12611000845932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000845932.